Wolverine

Wolverine 20 mg is supplied as a lyophilized powder, sealed in a light-protected vial to preserve peptide stability prior to reconstitution. Each vial carries a printed lot number, which ties that specific unit back to its Certificate of Analysis and batch-testing record — a detail that matters for anyone trying to keep protocols reproducible across shipments or over time. The total peptide content per vial is 20 mg, combining BPC-157 and TB-500 into a single blend rather than requiring two separate purchases. Because it's a lyophilized product, Wolverine needs to be reconstituted with an appropriate diluent before use in a research setting, and PrimeTime includes handling and reconstitution guidance with each unit specifically to support that step. This isn't a novel synthetic peptide with its own distinct sequence — it's a blend of two independently synthesized, independently characterized peptides packaged together, which is worth keeping in mind when comparing it to single-component vials of BPC-157 or TB-500 (both of which PrimeTime also carries at 10 mg each, if a lab wants to run the components separately for comparison). There's no minimum order quantity on Wolverine, so a single vial is enough to get a batch of protocols started. For research groups or institutions that need larger quantities on a recurring basis, PrimeTime offers bulk pricing on select bundles — that's handled directly through their team rather than the storefront, since institutional orders tend to have their own documentation and invoicing requirements.

The logic behind Wolverine 20 mg comes from what's already published on its two components individually, and the blend exists to let researchers study how those two mechanisms behave when present together rather than in separate assays. BPC-157 is a pentadecapeptide — a 15-amino-acid sequence — derived from a protective compound identified in gastric juice. The bulk of the research interest in BPC-157 centers on its apparent role in angiogenesis (new blood vessel formation) and fibroblast migration, both of which are upstream steps in tissue repair. Published work has looked at BPC-157 across a range of tissue models, including gut, tendon, and ligament, which is part of why it shows up so often in wound-healing and connective-tissue literature. The appeal for researchers isn't that it's a single dramatic mechanism — it's that BPC-157 seems to touch several of the early steps that have to happen before a tissue can actually repair itself. TB-500 is a synthetic, 7-amino-acid fragment of thymosin beta-4 (Ac-LKKTETQ), a naturally occurring 43-amino-acid protein involved in cell structure and movement. Its research profile centers on actin-binding activity — actin being one of the core structural proteins inside cells that governs how they move and reshape themselves. TB-500 has been studied for its association with cell migration, consistent with its actin-binding properties; broader claims involving new blood vessel formation and wound-healing cascades in the published literature largely derive from studies of the full-length thymosin beta-4 protein rather than the TB-500 fragment specifically. Putting the two in one vial isn't about creating a new molecule — it's a blend, not a fusion peptide, and each component retains its own independent mechanism. What the combined format offers is a way to design protocols around the interaction of two repair-adjacent pathways side by side, rather than running BPC-157 and TB-500 as two entirely separate arms of a study. For labs that specifically want to isolate one mechanism at a time, PrimeTime's single-component BPC-157 10 mg and TB-500 10 mg vials remain available, and using the blend alongside those individual vials is a reasonable way to build a comparative research design. As with any research peptide blend, the value of the data depends heavily on documentation — batch consistency, verified identity, and confirmed purity all matter more when two components are being studied together, since any variability in one peptide's concentration can confound interpretation of the interaction being studied.

Every batch of Wolverine 20 mg is independently verified before it ships. PrimeTime runs third-party HPLC (high-performance liquid chromatography) and mass spectrometry testing on each batch to confirm both purity and peptide identity — HPLC separates and quantifies the components present in a sample, while mass spectrometry confirms that what's present actually matches the expected molecular identity of BPC-157 and TB-500. Together, those two methods cover the two questions that matter most for a research blend: is it pure, and is it actually what it's labeled as. The current listed purity for Wolverine is 99%+, and each vial's Certificate of Analysis documents the specific result for that lot — not a generic, site-wide purity claim. The sample batch referenced on the product page, PTB-WOLV-20MG-0925, was analyzed on 8/27/2026 at 99% purity, and that COA is available for download from the buyer's account after purchase. Because the lot number is printed directly on the vial, it's straightforward to match a given unit back to its exact testing record rather than relying on a purity figure that isn't tied to the specific batch in hand. This batch-level traceability is really the core of what "quality" means for a research peptide blend — it's less about a single purity number and more about being able to verify, after the fact, that the vial on the bench matches its documentation. For labs that need to reference COAs across multiple purchases, PrimeTime maintains a dedicated Certificates of Analysis page where lot-specific records can be looked up.

Wolverine 20 mg is sold strictly for laboratory and research use. It is not a drug, dietary supplement, food, or cosmetic product, and it has not been evaluated by the FDA. It is not intended for human or animal consumption, and no diagnostic or therapeutic use is implied or supported by its sale. Purchase and use of Wolverine are intended for qualified researchers and laboratory professionals conducting in-vitro or preclinical research, and any handling should follow appropriate laboratory safety practices for peptide research materials.